CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 465 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04852666
NCT04852666N/ACompleted
CompareCT.gov

Comparative Effectiveness of Biologics or Small Molecule Therapies After Failure of Anti-TNF Treatment in Patients With Crohn's Disease and Ulcerative Colitis

University of North Carolina, Chapel Hill·observational·Posted Apr 21, 2021·Updated Jun 14, 2024

In Brief

An observational study for Crohn's Disease and Ulcerative Colitis. Completed, enrolled 465 participants across 2 sites.

Detailed Summary

The purpose of this study is to assess effectiveness of vedolizumab versus ustekinumab in patients with Crohn's disease and vedolizumab versus tofacitinib in patients with ulcerative colitis, after non-response to anti-tumor necrosis factor (TNF) medications, using data from two existing cohorts.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease, Ulcerative Colitis
CountriesUnited States
CollaboratorsPatient-Centered Outcomes Research Institute, Crohn's and Colitis Foundation

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedApr 21, 2021
Enrollment StartJul 25, 2019
Primary CompletionDec 15, 2022
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 5.2 years ago